公开(公告)号：US20150167005A1

公开(公告)日：2015-06-18

申请号：US14539831

申请日：2014-11-12

Applicant: ISIS PHARMACEUTICALS, INC.

Inventor： Susan M. Freier ,  Rosanne M. Crooke ,  Mark J. Graham ,  Kristina M. Lemonidis ,  Sanjay Bhanot ,  Diane Tribble ,  Andrew T. Watt

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  A61K45/06 ,  A61K48/00 ,  C12N2310/11 ,  C12N2310/321 ,  C12N2310/351 ,  C12N2320/30

Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

公开(公告)号：US08912160B2

公开(公告)日：2014-12-16

申请号：US14152825

申请日：2014-01-10

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Susan M. Freier ,  Rosanne M. Crooke ,  Mark J. Graham ,  Kristina M. Lemonidis ,  Sanjay Bhanot ,  Andrew T. Watt ,  Diane Tribble

IPC: C12N15/11 ,  A61K48/00 ,  C07H21/02 ,  C07H21/04

CPC classification number: C12N15/1137 ,  A61K45/06 ,  A61K48/00 ,  C12N2310/11 ,  C12N2310/321 ,  C12N2310/351 ,  C12N2320/30

Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

公开(公告)号：US08865674B2

公开(公告)日：2014-10-21

申请号：US13623337

申请日：2012-09-20

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Susan M. Freier ,  Sanjay Bhanot

IPC: C07H21/02 ,  C07H21/04 ,  A61K31/70 ,  C12N15/113 ,  C12Q1/68 ,  A61K31/711

CPC classification number: C12N15/1138 ,  A61K31/711 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/3525

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCGR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.

Abstract translation: 本文提供了用于减少动物中GCGR mRNA和蛋白质表达的方法，化合物和组合物。 这些方法，化合物和组合物可用于治疗，预防，延迟或改善代谢疾病，例如糖尿病或其症状。

公开(公告)号：US20140194492A1

公开(公告)日：2014-07-10

申请号：US14152825

申请日：2014-01-10

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Susan M. Freier ,  Rosanne M. Crooke ,  Mark J. Graham ,  Kristina M. Lemonidis ,  Sanjay Bhanot ,  Diane Tribble ,  Andrew T. Watt

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  A61K45/06 ,  A61K48/00 ,  C12N2310/11 ,  C12N2310/321 ,  C12N2310/351 ,  C12N2320/30

Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

Abstract translation: 本文公开了用于降低具有升高的LDL-C的个体中的LDL-C的反义化合物和方法。 另外公开了用于治疗，预防或改善高胆固醇血症和/或动脉粥样硬化的反义化合物和方法。 进一步公开的是用于降低冠心病风险的反义化合物和方法。 这样的方法包括向需要治疗的个体施用靶向PCSK9核酸的反义化合物。 施用的反义化合物包括gapmer反义寡核苷酸。

公开(公告)号：US20140107184A1

公开(公告)日：2014-04-17

申请号：US14137111

申请日：2013-12-20

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Eric E. Swayze ,  Susan M. Freier ,  Michael L. McCaleb

IPC: C12N15/113

CPC classification number: C12N15/1131 ,  C12N2310/11 ,  C12N2310/313 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/344 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/3525

Abstract: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.

公开(公告)号：US20160145617A1

公开(公告)日：2016-05-26

申请号：US14906047

申请日：2014-07-21

Applicant: ISIS PHARMACEUTICALS, INC.

Inventor： Holly Kordasiewicz ,  Eric E. Swayze ,  Susan M. Freier ,  Huynh-Hoa Bui

IPC: C12N15/113

CPC classification number: C12N15/113 ,  A61K31/711 ,  C07H21/02 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/345 ,  C12N2310/346 ,  C12N2310/321 ,  C12N2310/3525

Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.

Abstract translation: 本文公开了用于降低Tau mRNA和蛋白质表达的反义化合物和方法。 这些方法，化合物和组合物可用于治疗，预防或改善Tau相关疾病，病症和病症。

公开(公告)号：US20160068845A1

公开(公告)日：2016-03-10

申请号：US14814174

申请日：2015-07-30

Applicant: Isis Pharmaceuticals, Inc. ,  University Of Rochester

Inventor： C. Frank Bennett ,  Susan M. Freier ,  Robert A. MacLeod ,  Sanjay K. Pandey ,  Charles A. Thornton ,  Thurman Wheeler ,  Seng H. Cheng ,  Andrew Leger ,  Bruce M. Wentworth

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525 ,  C12Y207/11 ,  C12N2310/322 ,  C12N2310/3533 ,  C12N2310/3527

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.

公开(公告)号：US20160046945A1

公开(公告)日：2016-02-18

申请号：US14793622

申请日：2015-07-07

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Eric E. Swayze ,  Susan M. Freier ,  Michael L. McCaleb

IPC: C12N15/113

CPC classification number: C12N15/1131 ,  C12N2310/11 ,  C12N2310/313 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/344 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2310/3525

Abstract: Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.

公开(公告)号：US20150337303A1

公开(公告)日：2015-11-26

申请号：US14552436

申请日：2014-11-24

Applicant: ISIS PHARMACEUTICALS, INC.

Inventor： Rosanne M. Crooke ,  Mark J. Graham ,  Susan M. Freier ,  Marc Lim ,  Andrew Dibble

IPC: C12N15/113

CPC classification number: A61K31/7115 ,  A61K31/712 ,  A61K31/7125 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/323 ,  C12N2310/3341 ,  C12N2310/3525

Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Abstract translation: 本文公开了用于减少apo（a）以治疗，预防或改善与apo（a）或Lp（a）相关的疾病，病症或病症的反义化合物和方法。 与apo（a）或Lp（a）相关的某些疾病，病症或病症包括炎性，心血管和/或代谢疾病，病症或病症。 本文公开的反义化合物可用于治疗有需要的个体中的这些疾病，病症或病症。

公开(公告)号：US20150315594A1

公开(公告)日：2015-11-05

申请号：US14701999

申请日：2015-05-01

Applicant: Isis Pharmaceuticals, Inc.

Inventor： Thazha P. Prakash ,  Punit P. Seth ,  Eric E. Swayze ,  Susan M. Freier ,  Mark J. Graham ,  Rosanne M. Crooke

IPC: C12N15/113

CPC classification number: C07H19/20 ,  C07H15/04 ,  C07H21/02 ,  C07H21/04 ,  C12N15/1136 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2320/32 ,  C12N2310/3525 ,  C12N2310/3231

Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.

Abstract translation: 本文提供了用于减少动物中ANGPTL3 mRNA和蛋白质表达的方法，化合物和组合物。 本文还提供了用于还原动物体内脂质和/或葡萄糖的方法，化合物和组合物。 这样的方法，化合物和组合物可用于治疗，预防，延迟或改善有需要的个体的任何一种或多种心血管疾病和/或代谢疾病或其症状。